Mydecine Innovations Group Inc. (OTCMKTS:MYCOF – Get Free Report) fell 45% on Thursday . The stock traded as low as $1.10 and last traded at $1.10. Approximately 4,678 shares traded hands during trading, an increase of 31% from the average session volume of 3,575 shares. The stock had previously closed at $2.00.
Mydecine Innovations Group Trading Down 45.0%
The stock’s 50-day moving average price is $1.53 and its 200-day moving average price is $0.87.
Mydecine Innovations Group Company Profile
Mydecine Innovations Group (OTCMKTS:MYCOF) is a clinical‐stage biotechnology company dedicated to the research, development and commercialization of novel therapeutics derived from psychedelic and plant-based compounds. The company’s primary focus lies in advancing a pipeline of next‐generation product candidates targeting mental health disorders, addiction and other neurological conditions. Mydecine holds a portfolio of intellectual property that encompasses proprietary chemical entities, drug delivery systems and manufacturing processes for molecules such as 5-MeO-DMT analogs, ibogaine-derived compounds and psilocybin formulations.
Headquartered in Denver, Colorado, with additional research and manufacturing facilities in Vancouver, Canada, Mydecine operates a vertically integrated business model.
Read More
- Five stocks we like better than Mydecine Innovations Group
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Mydecine Innovations Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mydecine Innovations Group and related companies with MarketBeat.com's FREE daily email newsletter.
